The Indianapolis Zoo maintains a large collection of smooth dogfish (Mustelus canis). During the first several years of captivity, there was a period of high mortality in adult, wild-caught sharks in the collection. Smooth dogfish with superficial abrasions would rapidly succumb to infection and death, regardless of the treatment approach. Although the sharks did successfully produce viable offspring, there was an elevated pup mortality rate, with 0% of the pups reaching 1 yr of age during the same period of high mortality in adult sharks. This poor response to captivity prompted interest in the physiologic response of these animals to illness. The objective of this investigation was to establish a preliminary data set of hematologic and plasma chemistry reference intervals, along with select nutrient parameters specific to wild-caught adults maintained in prolonged captivity (i.e., greater than 22 mo). Blood samples were collected from 20 clinically healthy, male (n = 10) and female (n = 10) dogfish sharks at the Oceans facility at the Indianapolis Zoo. Although gender differences in mortality rate were not apparent, complete blood cell counts, plasma biochemical profiles, and select nutrient analyses were performed and analyzed accordingly. Statistically significant differences (P< or = 0.05) specific to sex were determined for parameters including packed cell volume (PCV), absolute and relative fine eosinophilic granulocytes, relative percentage of coarse eosinophilic granulocytes, globulins, the albumin/globulin ratio, total protein, phosphorus, iron, selenium and copper. White blood cell counts appear to be lower in this species compared to other captive elasmobranchs. Further research into appropriate hematology standards including nutritional parameters appears warranted.
1. In a double‐blind crossover study 10 healthy males received either placebo or omeprazole (40 mg day‐1) for 9 days, a single dose of phenytoin (300 mg) being taken on the seventh day. 2. Omeprazole significantly increased the area under the curve (0 to 72 h) of phenytoin (mean +/‐ s.e. mean) from 121.6 +/‐ 14.0 to 151.4 +/‐ 13.6 micrograms ml‐1 h) (P less than 0.01). 3. The peak concentration, and apparent elimination half‐life of phenytoin also tended to be increased though not significantly. 4. The omeprazole‐phenytoin interaction observed may be clinically important because of the low therapeutic index associated with phenytoin.
1. The comparative metabolism of fenfluramine was investigated in mouse, rat, dog and man following a single oral dose of 14C-(+/-)-fenfluramine hydrochloride (1 mg/kg), and also in rat after eight consecutive 12-h subcutaneous doses (24 mg/kg). 2. Main route of excretion of radioactivity in all species and at all doses was into urine (> 80%), with only minor amounts of radioactivity found in faeces. 3. From all species examined a total of 11 metabolites were observed in urine and plasma by t.l.c. and h.p.l.c. analysis and no metabolite was present in the plasma which was not present in urine. 4. All species dealkylate fenfluramine to the active metabolite norfenfluramine, to a relative greater or lesser extent, with plasma metabolic ratios (norfenfluramine/fenfluramine) showing inter-animal variation (rat >> dog >> mouse = man). 5. These differences are due to the efficient deamination of both compounds to polar inactive metabolites in man, with less dealkylation and lower plasma levels of norfenfluramine compared with the other species studied. 6. In conclusion, major species differences in the metabolism of (+/-)-fenfluramine, both qualitative and quantitative were observed, and no one species had a similar metabolic profile to that found in man.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.